Stromal cell-based immunotherapy in transplantation

Immunotherapy

Volumn 3, Issue 12, 2011, Pages 1471-1485

  Charles, Ronald ^a   Lu, Lina ^a,b   Qian, Shiguang ^a,b   Fung, John J ^a  

^a Digestive Disease Institute   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

allogeneic; hepatic stellate cell; immunosuppression; mesenchymal stem cell; Sertoli cells; tolerance

Indexed keywords

ALLOTRANSPLANTATION; AUTOIMMUNE DISEASE; CELL THERAPY; CELL TYPE; CLINICAL TRIAL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LANGERHANS CELL; LYMPHOID ORGAN; MESENCHYMAL STEM CELL; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PLACENTA; PRIORITY JOURNAL; REVIEW; SERTOLI CELL; SKIN ALLOGRAFT; STELLATE CELL; STROMA CELL; THYMUS;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; ISOANTIGENS; ORGAN TRANSPLANTATION; STROMAL CELLS;

EID: 81855217340     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.132     Document Type: Review

References (130)

1. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am. J. Transplant. 10(4 Pt 2), 961-972 (2010).
2. Kemmer N, Neff G. Recipient-based approach to tailoring immunosuppression in liver transplantation. Transplant. Proc. 42(5), 1731-1737 (2010).
3. Parham P. Elements of the immune system and their roles in defense. In: The Immune System. 2nd Ed. Paul WE (Ed.). Garland Science Publishing, NY, USA 1-34 (2005).
4. + thymocytes. Trends Immunol. 31(2), 71-79 (2010).
5. + regulatory T cells promiscuously accept thymic signals critical for their development. Proc. Natl Acad. Sci.
6. + medullary thymic epithelial cells. Nat. Immunol. 8(4), 351-358 (2007).
7. Anderson AO, Shaw S. T cell adhesion to endothelium: the FRC conduit system and other anatomic and molecular features which facilitate the adhesion cascade in lymph node. Semin. Immunol. 5(4), 271-282 (1993).
8. Bajénoff M, Egen JG, Koo LY et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 25(6), 989-1001 (2006).
9. Mueller SN, Matloubian M, Clemens DM et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl Acad. Sci.
10. Gardner JM, Devoss JJ, Friedman RS et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321(5890), 843-847 (2008).
11. O'Rand MG, Romrell LJ. Appearance of cell surface auto- and isoantigens during spermatogenesis in the rabbit. Dev. Biol. 55(2), 347-358 (1977).
12. Tung PS, Fritz IB. Specific surface antigens on rat pachytene spermatocytes and successive classes of germinal cells. Dev. Biol. 64(2), 297-315 (1978).
13. Griswold MD. The central role of Sertoli cells in spermatogenesis. Semin. Cell Dev. Biol. 9(4), 411-416 (1998).
14. Mital P, Kaur G, Dufour JM. Immunoprotective Sertoli cells: making allogeneic and xenogeneic transplantation feasible. Reproduction 139(3), 495-504 (2010).
15. Ferguson J, Scothorne RJ. Extended survival of pancreatic islet allografts in the testis of guinea-pigs. J. Anat. 124(Pt 1), 1-8 (1977).
16. Ferguson J, Scothorne RJ. Further studies on the transplantation of isolated pancreatic islets. J. Anat. 124(Pt 1), 9-20 (1977).
17. Naji A, Barker CF. The influence of histocompatibility and transplant site on parathyroid allograft survival. J. Surg. Res. 20(4), 261-267 (1976).
18. Whitmore WF, Gittes RF. Studies on the prostate and testis as immunologically privileged sites. Cancer Treat. Rep. 61(2), 217-222 (1977).
19. Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant. 2(2), 123-129 (1993).
20. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46(2), 317-322 (1997).
21. Dufour JM, Lord SJ, Kin T et al. Comparison of successful and unsuccessful islet/Sertoli cell cotransplant grafts in streptozotocin-induced diabetic mice. Cell Transplant. 16(10), 1029-1038 (2008).
22. Li Y, Xue WJ, Tian XH et al. Study on systemic immune tolerance induction in rat islet transplantation by intravenous infusion of Sertoli cells. Transplantation 89(12), 1430-1437 (2010).
23. Shamekh R, El-Badri NS, Saporta S et al. Sertoli cells induce systemic donor-specific tolerance in xenogenic transplantation model. Cell Transplant 15(1), 45-53 (2006).
24. Willing AE, Sudberry JJ, Othberg AI et al. Sertoli cells decrease microglial response and increase engraftment of human hNT neurons in the hemiparkinsonian rat striatum. Brain Res. Bull. 48(4), 441-444 (1999).
25. Sanberg PR, Borlongan CV, Saporta S, Cameron DF. Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nat. Biotechnol. 14(13), 1692-1695 (1996).
26. Yang H, Wright JR Jr. Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Transplantation 67(6), 815-820 (1999).
27. Yin Z, Chen D, Hu F et al. Cotransplantation with xenogenetic neonatal porcine Sertoli cells significantly prolongs islet allograft survival in nonimmunosuppressive rats. Transplantation 88(3), 339-345 (2009).
28. Shamekh R, El-Badri NS, Saporta S et al. Sertoli cells induce systemic donor-specific tolerance in xenogenic transplantation model. Cell Transplant 15(1), 45-53 (2006).
29. Li Y, Xue WJ, Tian XH et al. Study on systemic immune tolerance induction in rat islet transplantation by intravenous infusion of Sertoli cells. Transplantation 89(12), 1430-1437 (2010).
30. Lim HG, Lee HM, Oh BC, Lee JR. Cell-mediated immunomodulation of chemokine receptor 7-expressing porcine Sertoli cells in murine heterotopic heart transplantation. J. Heart Lung Transplant. 28(1), 72-78 (2009).
31. Leventhal JR, Sakiyalak P, Witson J et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation 57, 974-978 (1994).
32. Suarez-Pinzon W, Korbutt GS, Power R, Hooton J, Rajotte RV, Rabinovitch A. Testicular Sertoli cells protect islet b cells from autoimmune destruction in NOD mice by a transforming growth factor b1- dependent mechanism. Diabetes 49(11), 1810-1818 (2000).
33. Fallarino F, Luca G, Calvitti M et al. Therapy of experimental Type 1 diabetes by isolated Sertoli cell xenografts alone. J. Exp. Med. 206(11), 2511-2526 (2009).
34. Luca G, Calvitti M, Nastruzzi C et al. Encapsulation, in vitro characterization, and in vivo biocompatibility of Sertoli cells in alginate-based microcapsules. Tissue Eng. 13(3), 641-648 (2007).
35. Emerich DF. Sertoli cell grafts for Huntington's disease. An opinion. Neurotox. Res. 5(8), 567 (2004).
36. Dufour JM, Rajotte RV, Korbutt GS, Emerich DF. Harnessing the immunomodulatory properties of Sertoli cells to enable xenotransplantation in Type I diabetes. Immunol. Invest. 32(4), 275-297 (2003).
37. Valdes-Gonzalez RA, Dorantes LM, Garibay GN et al. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4 year study. Eur. J. Endocrinol. 153, 419-427 (2005).
38. Li Y, Xue WJ, Tian XH et al. Study on systemic immune tolerance induction in rat islet transplantation by intravenous infusion of Sertoli cells. Transplantation 89(12), 1430-1437 (2010).
39. De Cesaris P, Filippini A, Cervelli C et al. Immunosuppressive molecules produced by Sertoli cells cultured in vitro: biological effects on lymphocytes. Biochem. Biophys. Res. Commun. 186(3), 1639-1646 (1992).
40. Selawry HP, Kotb M, Herrod HG, Lu ZN. Production of a factor, or factors, suppressing IL 2 production and T cell proliferation by Sertoli cell-enriched preparations. A potential role for islet transplantation in an immunologically privileged site. Transplantation 52, 846-850 (1991).
41. Takeda Y, Gotoh M, Dono K et al. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabetologia 41, 315-321 (1998).
42. Bladergroen BA, Strik MC, Bovenschen N et al. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J. Immunol. 166(5), 3218-3225 (2001).
43. Cunningham TD, Jiang X, Shapiro DJ. Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol. 245(1), 32-41 (2007).
44. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on isletb cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl Acad. Sci.
45. Kang SM, Schneider DB, Lin Z et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3(7), 738-743 (1997)
46. Suarez-Pinzon W, Korbutt GS, Power R et al. Testicular Sertoli cells protect islet b cells from autoimmune destruction in NOD mice by a transforming growth factor b1-dependent mechanism. Diabetes 49(11), 1810-1818 (2000).
47. Kang SM, Schneider DB, Lin Z et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3(7), 738-43 (1997).
48. Qian S, Thai NL, Lu L, Fung JJ, Thomson AW. Liver transplant tolerance: mechanistic insights from animal models, with particular reference to the mouse. Transplant. Rev. 11, 151-164 (1997).
49. Cantor HM, Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 215, 744-745 (1967).
50. Benseler V, McCaughan GW, Schlitt HJ et al. The liver: a special case in transplantation tolerance. Semin. Liver Dis. 27, 194-213 (2007).
51. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J. Hepatology 50, 1247-1257 (2009).
52. Knolle PA. Involvement of the liver in the induction of CD8 T cell tolerance towards oral antigen Z. Gastroenterology 44(1), 51-56 (2006).
53. Yu MC, Chen CH, Liang X et al. Inhibition of T cell responses by hepatic stellate cells via B7 H1-mediated T cell apoptosis in mice. Hepatology 40(6), 1312-1321 (2004).
54. Giampieri MP, Jezequel AM, Orlandi F. The lipocytes in normal human liver. A quantitative study. Digestion 22(4), 165-169 (1981).
55. Jezequel AM, Novelli G, Venturini C, Orlandi F. Quantitative analysis of the perisinusoidal cells in human liver; the lipocytes. Front. Gastrointest. Res. 8, 85-90 (1984).
56. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88(1), 125-172 (2008).
57. Chen CH, Kuo LM, Chang Y et al. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 44(5), 1171-1181 (2006).
58. Qian S, Lu L, Fu F et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J. Immunol. 158(10), 4654-4661 (1997).
59. Chen CH, Shu KH, Su YH et al. Cotransplantation of hepatic stellate cells attenuates the severity of graft-versus-host disease. Transplant. Proc. 42(3), 971-915 (2010).
60. Chen CH, Kuo LM, Chang Y et al. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 44(5), 1171-1181 (2006).
61. + regulatory T cells in an IL 2-dependent manner. Transplantation 86(11), 1492-1502 (2008).
62. Boros P, Ochando JC, Chen SH, Bromberg JS. Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum. Immunol. 71(11), 1061-1066 (2010).
63. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32(1), 19-25 (2011).
64. Chou HS, Hsieh CC, Yang HR et al. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology 53(3), 1007-1019 (2011).
65. Lees JR, Azimzadeh AM, Bromberg JS. Myeloid derived suppressor cells in transplantation. Curr. Opin Immunol. 23(5), 692-697 (2011).
66. Caplan AI. Mesenchymal stem cells. J. Orthop. Res. 9, 641-650 (1991).
67. Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 7, 211-228 (2001).
68. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294-1301 (2006).
69. Lee RH, Kim B, Choi I et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol. Biochem. 14, 311-324 (2004).
70. Mitchell JB, McIntosh K, Zvonic S et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 24, 376-385 (2006).
71. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC like cells from umbilical cord. Stem Cells 21, 105-110 (2003).
72. Lee OK, Kuo TK, Chen WM et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103, 1669-1675 (2004).
73. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22, 1338-1345 (2004).
74. Villaron EM, Almeida J, Lopez-Holgado N et al. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica 89, 1421-1427 (2004).
75. Roufosse CA, Direkze NC, Otto WR et al. Circulating mesenchymal stem cells. Int. J. Biochem. Cell Biol. 36, 585-597 (2004).
76. In 't Anker PS, Noort WA, Scherjon SA et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88(8), 845-852 (2003).
77. In't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 102, 1548-1549 (2003).
78. De Coppi P, Bartsch G Jr, Siddiqui MM et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25, 100-106 (2007).
79. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002).
80. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57, 11-20 (2003).
81. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171, 3426-3434 (2003).
82. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397 (2003).
83. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48 (2002).
84. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837-3844 (2003).
85. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722-3729 (2003).
86. + T cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 90, 516-525 (2005).
87. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 105, 2214-2219 (2005).
88. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005).
89. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13, 263-271 (2004).
90. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120-4126 (2005).
91. +-derived and monocyte derived dendritic cells. J. Immunol. 177, 2080-2087 (2006).
92. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397 (2003).
93. Mellor AL, Munn DH. Tryptophan catabolism and T cell tolerance: immunosuppression by starvation? Immunol. Today 20, 469-473 (1999).
94. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459-468 (2002).
95. Liu XQ, Wang X. Indoleamine 2,3-dioxygenase in tumor induced tolerance. Chin. Med. J. (Engl.) 122(24), 3072-3077 (2009).
96. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12), 4619-4621 (2004).
97. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF b signaling in regulation of cell growth and differentiation. Immunol. Lett. 82(1-2), 85-91 (2002).
98. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305(1), 33-41 (2005).
99. Ball LM, Bernardo ME, Roelofs H et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110(7), 2764-2767 (2007).
100. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419), 1439-1441 (2004).
101. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56(4), 1175-1186 (2007).
102. Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 26(7), 1913-1919 (2008).
103. Fiorina P, Jurewicz M, Augello A et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune Type 1 diabetes. J. Immunol. 183(2), 993-1004 (2009).
104. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase 2 and -9. Diabetes 58(8), 1797-1806 (2009).
105. Li FR, Wang XG, Deng CY, Qi H, Ren LL, Zhou HX. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clin. Exp. Immunol. 161(2), 357-363 (2010).
106. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30(1), 42-48 (2002).
107. Casiraghi F, Azzollini N, Cassis P et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181(6), 3933-3946 (2008).
108. Ringdén O, Uzunel M, Rasmusson et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10), 1390-1397 (2006).
109. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371(9624), 1579-1586 (2008).
110. Ringden O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract. Res. Clin. Haematol. 24(1), 65-72 (2011).
111. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant. Proc. 39(10), 3358-3362 (2007).
112. Ho S-J, Dyson P, Rawling T et al. Mesenchymal stem cells for treatment of steroid resistant graft-versus-host disease. Biol. Blood Marrow Transplant. 13, 46-47 (2009).
113. Kebriaei P, Isola L, Bahceci E et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15(7), 804-811 (2009).
114. Von Bonin M, Stölzel F, Goedecke A et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 43(3), 245-251 (2009).
115. Lucchini G, Introna M, Dander E et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol. Blood Marrow Transplant. 16(9), 1293-1301 (2010).
116. Prasad VK, Lucas KG, Kleiner GI et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol. Blood Marrow Transplant. 17(4), 534-541 (2011).
117. Ning H, Yang F, Jiang M et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22(3), 593-599 (2008).
118. Dahlke MH, Hoogduijn M, Eggenhofer E et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 88(5), 614-619 (2009).
119. Hoogduijn MJ, Popp FC, Grohnert A et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation(MISOT). Transplantation 90(2), 124-126 (2010).
120. Sbano P, Cuccia A, Mazzanti B et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch. Dermatol. Res. 300(3), 115-124 (2008).
121. Magatti M, De Munari S, Vertua E et al. Human amnion mesenchyme harbors cells with allogeneic T cell suppression and stimulation capabilities. Stem Cells 26(1), 182-192 (2008).
122. Banas RA, Trumpower C, Bentlejewski C et al. Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum. Immunol. 69(6), 321-328 (2008).
123. Chang CJ, Yen ML, Chen YC et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24(11), 2466-2477 (2006).
124. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 105(5), 2214-2219 (2005).
125. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13(3), 263-271 (2004).
126. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10), 3499-3506 (2007).
127. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105(10), 4120-4126 (2005).
128. Magatti M, De Munari S, Vertua E et al. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant. 18(8), 899-914 (2009).
129. Parolini O, Caruso M. Review: preclinical studies on placenta-derived cells and amniotic membrane: an update. Placenta 32(Suppl. 2), S186-S195 (2011).
130. Gores PF, Hayes DH, Copeland MJ et al. Long-term survival of intratesticular porcine islets in nonimmunosuppressed beagles. Transplantation 75(5), 613-618 (2003).